W-Y Zhang1, J Wang, A-Z Li. 1. Department of Endocrine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China. laz168@163.com.
Abstract
OBJECTIVE: The aim of this study was to observe the protective effects of SGLT-2 inhibitors on diabetic cardiomyopathy. MATERIALS AND METHODS: After constructing a diabetic rat model, the effects of SGLT-2 (Sodium-Glucose Cotransporter-2) inhibitors and miR-30d on cardiac function in rats were investigated by cardiac echocardiography, hematoxylin-eosin (HE) staining, and immunohistochemical methods. At the same time, changes in autophagy levels in rats were detected by Western blot (WB) experiments. RESULTS: SGLT-2 inhibitors improved the cardiac function of diabetic rats, and alleviated the pathological damage of myocardial tissue. Besides, knocking down miR-30d prevented the decrease of cardiac function in diabetic rats. Moreover, miR-30d could regulate the expression of the KLF9/VEGFA pathway and inhibit autophagy in rats. CONCLUSIONS: SGLT-2 inhibitors can regulate the autophagy level in diabetic rats through the miR-30d/KLF9/VEGFA pathway, thereby improving cardiac function.
OBJECTIVE: The aim of this study was to observe the protective effects of SGLT-2 inhibitors on diabetic cardiomyopathy. MATERIALS AND METHODS: After constructing a diabeticrat model, the effects of SGLT-2 (Sodium-Glucose Cotransporter-2) inhibitors and miR-30d on cardiac function in rats were investigated by cardiac echocardiography, hematoxylin-eosin (HE) staining, and immunohistochemical methods. At the same time, changes in autophagy levels in rats were detected by Western blot (WB) experiments. RESULTS:SGLT-2 inhibitors improved the cardiac function of diabeticrats, and alleviated the pathological damage of myocardial tissue. Besides, knocking down miR-30d prevented the decrease of cardiac function in diabeticrats. Moreover, miR-30d could regulate the expression of the KLF9/VEGFA pathway and inhibit autophagy in rats. CONCLUSIONS:SGLT-2 inhibitors can regulate the autophagy level in diabeticrats through the miR-30d/KLF9/VEGFA pathway, thereby improving cardiac function.
Authors: Daniel Jakubik; Alex Fitas; Ceren Eyileten; Joanna Jarosz-Popek; Anna Nowak; Pamela Czajka; Zofia Wicik; Harald Sourij; Jolanta M Siller-Matula; Salvatore De Rosa; Marek Postula Journal: Cardiovasc Diabetol Date: 2021-02-27 Impact factor: 9.951
Authors: Shawn Veitch; Makon-Sébastien Njock; Mark Chandy; M Ahsan Siraj; Lijun Chi; HaoQi Mak; Kai Yu; Kumaragurubaran Rathnakumar; Carmina Anjelica Perez-Romero; Zhiqi Chen; Faisal J Alibhai; Dakota Gustafson; Sneha Raju; Ruilin Wu; Dorrin Zarrin Khat; Yaxu Wang; Amalia Caballero; Patrick Meagher; Edward Lau; Lejla Pepic; Henry S Cheng; Natalie J Galant; Kathryn L Howe; Ren-Ke Li; Kim A Connelly; Mansoor Husain; Paul Delgado-Olguin; Jason E Fish Journal: Cardiovasc Diabetol Date: 2022-02-24 Impact factor: 9.951